H1N1 Vaccine Table
A simplified table of the FDA-approved vaccines against the 2009 H1N1 virus is provided here, with a focus on age and dose recommendations. For complete data, see this week's MMWR.
|
Age |
Formulation(s) Available |
Dose, mL |
No. Doses |
|
6-23 mos |
IM injection |
0.25 |
2 |
|
24-35 mos |
IM injection |
0.25 |
2 |
|
Nasal spray |
0.2 |
2 | |
|
36-47 mos |
IM injection |
0.5 |
2 |
|
Nasal spray |
0.2 |
2 | |
|
4-9 y |
IM injection |
0.5 |
2 |
|
Nasal spray |
0.2 |
2 | |
|
10-17 y |
IM injection |
0.5 |
1 |
|
Nasal spray |
0.2 |
1 | |
|
18-49 y |
IM injection |
0.5 |
1 |
|
Nasal spray |
0.2 |
1 | |
|
>49 y |
IM injection |
0.5 |
1 |
The IM shots contain inactivated virus, and the nasal spray (from MedImmune) contains attenuated virus. Prefilled syringes do not contain mercury (that is, 25 microg Hg per 0.5 mL of vaccine, in the form of thimerosal preservative). When 2 doses are recommended, they are administered approximately 4 weeks apart.
The nasal spray vaccine is indicated for healthy, nonpregnant persons aged 2-49 years and should not be administered to persons with asthma. The dose of the nasal spray is divided equally between each nostril.
Note: These data are for informational purposes only and should be confirmed by referring to authoritative sources (eg, the CDC) and/or a treating healthcare professional.
* Latter approved by FDA for age group on 11/12/09.
